Externes Scientific Advisory Board (SAB)

The SAB is set up to consult the Company with regard to strategic options and future perspectives within its research and development activities. The goal of the SAB is thus to further strengthen MorphoSys’s leadership position in discovery and clinical development of antibody and peptide-based therapies for cancer, inflammation and other therapeutic fields.

Dr. Günter R. Adolf

Strategic Scientific Advisory Board Member

Further Information

Dr. Günter R. Adolf

Strategic Scientific Advisory Board Member

Current professional activities
  • Department of Biochemistry and Molecular Cell Biology of the University of Vienna, Honorary Lecturer
  • Conversations with start-ups in non-oncology area
Professional experience
  • Boehringer Ingelheim Oncology Drug Discovery Center, Vienna, Austria, Vice President and Deputy Head
Expertise
  • Expertise in drug discovery and development, life sciences, small molecules & biologics

 

Prof. Dr. Bruce D. Cheson

Strategic Scientific Advisory Board Member

Further Information

Prof. Dr. Bruce D. Cheson

Strategic Scientific Advisory Board Member

Current professional activities
  • Devision of Hematology and Oncology, Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington DC/US, Prof. of Medicine and Deputy Chief
  • Medstar Health and Georgetown University Hospital, Waschington DC/US, Fellowship Director
Professional experience
  • Nation Cancer Institute´s Clinical Investigations Branch within the Cancer Therapy Evaluation Program, Head of the Medicine Section
  • NCI´s Lymphoma Clinic, Senior staff physican
  • University of Utah, Assistant professor of medicine in hematology and oncology
Expertise
  • Expertise in development and evaluation therapeutic approaches for hematologic malignancies

 

Dr. Lillian L. Siu

Strategic Scientific Advisory Board Member

Further Information

Dr. Lillian L. Siu

Strategic Scientific Advisory Board Member

Current professional activities
  • Division of Medical Oncology/Hematology, Department of Medicine, Princess Margaret Hospital, University Health Network, Senior Medical Oncologist, Director of Phase I Program & Co-Director of Robert and Maggie Bras and Family Drug Development Program, BMO Chair in Precision Genomics
  • Faculty of Medicine, University of Toronto, Professor
Professional expertice
  • Doctor of Medicine (MD), University of Toronto, Faculty of Medicine
  • Certification in Internal Medicine (FRCPC), The Royal College of Physicians and Surgeons of Canada
Expertise
  • Expertise in new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies; genomics initiatives and immuno-oncology trials

 

Dr. Ross L. Levine

Strategic Scientific Advisory Board Member

Further Information

Dr. Ross L. Levine

Strategic Scientific Advisory Board Member

Current professional activities
  • Human Oncology and Pathogenesis Program, Center for Epigenetics Research Member
  • Leukemia Service, Department of Medicine Attending Physician
  • Laurence Joseph Dineen, Chair in Leukemia Research
  • MSK Center for Hematologic Malignancies Memorial Sloan Kettering Cancer Center, Director
  • Weill Cornell Medical College, Professor of Medicine
     
Professional experience
  •  Doctor of Medicine (MD), Johns Hopkins University School of Medicine, Baltimore
  • Intern/Resident in Internal Medicine, Massachusetts General Hospital, Boston, MA
  • Fellow in Hematology/Oncology, Dana-Farber/Harvard Cancer Center
     
Expertise
  • Expertise in research and treating blood and bone marrow cancers, including acute myeloid leukemia and the chronic myeloproliferative neoplasms polycythemia vera, essential thrombocytosis, and primary myelofibrosis